Filing Details

Accession Number:
0001181431-15-003650
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-02 17:34:01
Reporting Period:
2015-02-26
Filing Date:
2015-03-02
Accepted Time:
2015-03-02 17:34:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1382911 Orexigen Therapeutics Inc. OREX Pharmaceutical Preparations (2834) 651178822
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1470885 D Mark Booth C/o Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla CA 92037
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-26 50,000 $1.66 53,810 No 4 M Direct
Common Stock Disposition 2015-02-26 50,000 $5.68 3,810 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-02-26 50,000 $0.00 50,000 $1.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
563,924 2021-07-24 No 4 M Direct
Footnotes
  1. The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2014.
  2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2014.
  3. Weighted average from 16 transactions with prices ranging from $5.66 to $5.85. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price.
  4. 1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the Reporting Person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
  5. N/A